337 related articles for article (PubMed ID: 29297955)
1. Predictive factors of response to IVIG in pediatric immune thrombocytopenic purpura.
Higashide Y; Hori T; Yoto Y; Kabutoya H; Honjo S; Sakai Y; Nojima M; Yoda M; Yamamoto M; Tsutsumi H
Pediatr Int; 2018 Apr; 60(4):357-361. PubMed ID: 29297955
[TBL] [Abstract][Full Text] [Related]
2. Identification of predictive factors for response to intravenous immunoglobulin treatment in children with immune thrombocytopenia.
Morimoto Y; Yoshida N; Kawashima N; Matsumoto K; Kato K
Int J Hematol; 2014; 99(5):597-602. PubMed ID: 24573984
[TBL] [Abstract][Full Text] [Related]
3. Different dosages of intravenous immunoglobulin (IVIg) in treating immune thrombocytopenia with long-term follow-up of three years: Results of a prospective study including 167 cases.
Zhou Z; Qiao Z; Li H; Luo N; Zhang X; Xue F; Yang R
Autoimmunity; 2016; 49(1):50-7. PubMed ID: 26525513
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura.
El Alfy MS; Mokhtar GM; El-Laboudy MA; Khalifa AS
Acta Haematol; 2006; 115(1-2):46-52. PubMed ID: 16424649
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immune globulin versus intravenous anti-D immune globulin for the treatment of acute immune thrombocytopenic purpura.
Shahgholi E; Vosough P; Sotoudeh K; Arjomandi K; Ansari S; Salehi S; Faranoush M; Ehsani MA
Indian J Pediatr; 2008 Dec; 75(12):1231-5. PubMed ID: 19190878
[TBL] [Abstract][Full Text] [Related]
6. Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama.
Watts RG
Clin Pediatr (Phila); 2004 Oct; 43(8):691-702. PubMed ID: 15494875
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of IVIG response in relation to Th1/Th2 cytokines in pediatricm immune thrombocytopenia.
Chen YY; Zhou YQ; Zhao N; Zhang Y; Xu WQ; Tang YM
Cytokine; 2019 Aug; 120():234-241. PubMed ID: 31129375
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of initial use of intravenous immunoglobulin and prednisolone treatments in childhood idiopathic thrombocytopenic purpur.
Ou CY; Hsieh KS; Chiou YH; Chang YH; Ger LP
Acta Paediatr Taiwan; 2006; 47(5):226-31. PubMed ID: 17352309
[TBL] [Abstract][Full Text] [Related]
9. Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.
Blackhouse G; Xie F; Levine MA; Campbell K; Assasi N; Gaebel K; O'Reilly D; Tarride J; Goeree R
J Popul Ther Clin Pharmacol; 2012; 19(2):e166-78. PubMed ID: 22580389
[TBL] [Abstract][Full Text] [Related]
10. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
[TBL] [Abstract][Full Text] [Related]
11. Treatment of childhood acute immune thrombocytopenic purpura with high-dose methylprednisolone, intravenous immunoglobulin, or the combination of both.
Gereige RS; Barrios NJ
P R Health Sci J; 2000 Mar; 19(1):15-8. PubMed ID: 10761200
[TBL] [Abstract][Full Text] [Related]
12. First Line Treatments for Newly Diagnosed Primary Immune Thrombocytopenia in Children: A Systematic Review and Network Meta-analysis.
Acero-Garcés DO; García-Perdomo HA
Curr Pediatr Rev; 2020; 16(1):61-70. PubMed ID: 31656149
[TBL] [Abstract][Full Text] [Related]
13. Retrospective evaluation of children with immune thrombocytopenic purpura and factors contributing to chronicity.
Güngör T; Arman Bilir Ö; Koşan Çulha V; Güngör A; Kara A; Azık FM; Yaralı HN
Pediatr Neonatol; 2019 Aug; 60(4):411-416. PubMed ID: 30470618
[TBL] [Abstract][Full Text] [Related]
14. The effect of ABO and Rh blood type on the response to intravenous immune globulin (IVIG) in children with immune thrombocytopenic purpura (ITP).
Sturgill MG; Nagabandi SR; Drachtman RA; Ettinger AG; Rubin J; Ettinger LJ
J Pediatr Hematol Oncol; 1997; 19(6):523-5. PubMed ID: 9407938
[TBL] [Abstract][Full Text] [Related]
15. Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin.
Tarantino MD; Madden RM; Fennewald DL; Patel CC; Bertolone SJ
J Pediatr; 1999 Jan; 134(1):21-6. PubMed ID: 9880444
[TBL] [Abstract][Full Text] [Related]
16. Treatment, outcome, and cost of care in children with idiopathic thrombocytopenic purpura.
Kumar M; Vik TA; Johnson CS; Southwood ME; Croop JM
Am J Hematol; 2005 Mar; 78(3):181-7. PubMed ID: 15726607
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of childhood chronic immune thrombocytopenia: A 38-year experience from a single tertiary center in Thailand.
Chotsampancharoen T; Sripornsawan P; Duangchoo S; Wongchanchailert M; McNeil E
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28453897
[TBL] [Abstract][Full Text] [Related]
18. Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children.
Tarantino MD; Young G; Bertolone SJ; Kalinyak KA; Shafer FE; Kulkarni R; Weber LC; Davis ML; Lynn H; Nugent DJ;
J Pediatr; 2006 Apr; 148(4):489-94. PubMed ID: 16647411
[TBL] [Abstract][Full Text] [Related]
19. Possible lower rate of chronic ITP after IVIG for acute childhood ITP an analysis from registry I of the Intercontinental Cooperative ITP Study Group (ICIS).
Tamminga R; Berchtold W; Bruin M; Buchanan GR; Kühne T
Br J Haematol; 2009 Jul; 146(2):180-4. PubMed ID: 19466971
[TBL] [Abstract][Full Text] [Related]
20. Initial Management of Childhood Acute Immune Thrombocytopenia: Single-Center Experience of 32 Years.
Yildiz I; Ozdemir N; Celkan T; Soylu S; Karaman S; Canbolat A; Dogru O; Erginoz E; Apak H
Pediatr Hematol Oncol; 2015; 32(6):406-14. PubMed ID: 26154620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
